Lupin receives US FDA approval for generic Tolvaptan Tablets EP News Bureau Apr 24, 2025 Company secures 180-day marketing exclusivity as first-to-file applicant for bioequivalent to Jynarque
Lupin receives U.S. FDA approval for generic Ipratropium Bromide nasal spray EP News Bureau Feb 11, 2025 Approval allows marketing of generic equivalent of Atrovent Nasal Spray in the U.S.
Lupin and Natco secure US FDA approval for generic Bosentan tablets for oral suspension EP News Bureau Feb 10, 2025 Natco receives first-to-file exclusivity for Bosentan Tablets for Oral Suspension, 32 mg, in the US market
Lupin secures FDA approval for generic Emtricitabine and Tenofovir Alafenamide tablets EP News Bureau Dec 18, 2024 Lupin to launch generic version of Descovy with 180-day exclusivity, targeting HIV treatment market